socalTECH

MAY 15, 2013

Los Angeles-based Kite Pharma , a biotechnology company developing immunotherapies for cancer, said today that it has raised $35M in its Series A funding round. Kite Pharma said the round included $20M in new funding plus conversion of $15M in outstanding promissory notes. READ MORE>>.

Venture Capital 159

Venture Capital Los Angeles Capital Funding 159

socalTECH

JANUARY 17, 2014

Los Angeles-based Kite Pharma announced this morning that it has named a new VP. kite pharma pharmaceutical executive amgen lifescience biotech cancer' The biotechnology company--which is developing treatments for cancer--said it has named Rizwana F. Sproule, Ph.D. as Vice President, Regulatory Affairs. READ MORE>>.

Los Angeles 138

Los Angeles Angel Develop Development 138

socalTECH

MARCH 19, 2015

Montgomery is currently the CEO of Cardeas Pharma, and was a SVP at Gilead Sciences; he also was CEO of Corus Pharma, and served at PathoGenesis Corporation. xencor board executive biotech lifescience bruce montgomery ardeas pharma' READ MORE>>.

Monrovia 100

Monrovia Develop Development 100

socalTECH

OCTOBER 1, 2018

San Diego-based VelosBio , a biotech startup developing novel antibody-drug conjugates to treat hematological cancers and solid tumours, has raised $58M in a funding round. VelosBio is led by Dave Johnson, the former CEO of Acerta Pharma. READ MORE>>.

San Diego 113

San Diego Study Funding Capital 113

socalTECH

MAY 7, 2015

San Diego-based biotech developer aTyr Pharma is debuting in its IPO this morning, after pricing its IPO at $14.00 aTyr Pharma was venture backed by Fidelity Investments, Domain Associate, Polaris Partners, Alta Partners, Cardinal Partners, Sofinnova Ventures, and others. per share last night.

San Diego 100

San Diego Pricing Invest Marketing 100

socalTECH

APRIL 7, 2015

San Diego-based biopharmacetuicals firm aTyr Pharma has filed for an IPO, saying in a filing with the SEC that it is looking to raise up to $86.25M in an public offering on the NASDAQ Global Market as LIFE. aTyr Pharma is developing treatments for rare diseases, initially focusing on immune regulation issues. READ MORE>>.

San Diego 100

San Diego Acquisition Marketing Capital 100

socalTECH

DECEMBER 2, 2014

avanir pharmaceuticals merger acquisition otsuka biotech lifescience pharma' Avanir Pharmaceuticals said it was advised by Centerview Partners LLC and Latham & Watkins, LLP in the deal. READ MORE>>.

Acquisition 164

Acquisition Company Companies 164

SoCal Tech Calendar

NOVEMBER 6, 2016

Saturday, November 12, 2016 -- Caltech Entrepreneurs Forum - Biotech. Gordon Binder, Venture Capital investor, former Chairman and CEO of Amgen, and Trustee Emeritus of both Caltech and MIT keynotes the Caltech Entrepreneurs Forum program “Entrepreneurs in a Biotech Age”. See [link] (more)

CalTech 100

CalTech Entrepreneur Startup Venture Capital 100

Xconomy

MARCH 7, 2019

Chinese pharma company BeiGene has agreed to pay Ambrx $10 million upfront to experiment with technology the biotech has developed in a bid accelerate BeiGene’s search for new protein drugs for cancer treatment. La Jolla, CA-based Ambrx was founded in 2003, one of the slew of biotechs launched by.

Develop 79

Develop Development Technology Product 79

SoCal Tech Calendar

NOVEMBER 11, 2016

Saturday, November 12, 2016 -- Entrepreneurs in a Biotech Moment. Gordon Binder, Venture Capital investor, former Chairman and CEO of Amgen, and Trustee Emeritus of both Caltech and MIT, leads the November Caltech Entrepreneurs Forum program, "Entrepreneurs in a Biotech Age." Caltech Entrepreneurs Forum.

Entrepreneur 100

Entrepreneur CalTech Southern California Startup 100

socalTECH

MAY 10, 2013

Thousand Oaks-based biotech giant Amgen said Thursday that it is in a joint venture with Chinese company Zhejiang Beta Pharma , to commercialize the firm''s Vectibix (panitumumab) product in the Chinese market. and that Zhejiang Beta Pharma will own 51 percent of the company, with Amgen owning the remaining 49 percent.

Thousand Oaks 138

Thousand Oaks Marketing Product Company 138

Xconomy

JULY 2, 2020

MEI Pharma and its Swiss partner Helsinn are ending a Phase 3 study of an investigational cancer drug for patients with acute myeloid leukemia (AML) after an interim analysis indicated it was unlikely to meet the trial’s main goal of helping patients live longer. Under the deal.

San Diego 86

San Diego Study Help Company 86

socalTECH

JUNE 2, 2014

Santa Monica-based biopharmaceuticals firm Kite Pharma , which is developing products for the treatment of cancer, said today that it has named David D. cancer biotech lifescience amgen executive pharmaceutical pharma kite' Chang, M.D., as its new Executive Vice President, Research and Development, and Chief Medical Officer.

Santa Monica 100

Santa Monica UCLA Research Los Angeles 100

Xconomy

JANUARY 9, 2020

San Diego startup DTx Pharma has raised $10.6 The sum includes an undisclosed amount from Eli Lilly (NYSE: LLY ), which has made a number of investments in biotechs pursuing RNA-focused technologies. million to advance technology it has developed that uses fatty acids in an effort to overcome delivery and distribution issues.

San Diego 68

San Diego Invest Technology Startup 68

Xconomy

FEBRUARY 28, 2019

Equillium, a biotech that’s looking to develop an antibody drug for immuno-inflammatory diseases, has added a form of renal disease to the indications for which it aims to develop medicines. Equillium was formed to advance. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Bradbury 85

Bradbury Develop Development Company 85

socalTECH

FEBRUARY 8, 2017

The biotech industry in Southern California relies on a large number of researchers, many foreign-born, who come to the United States as students for advanced degrees; in recent years, studies have found that foreign students make up more than 90 percent of students in U.S. READ MORE>>.

Southern California 100

Southern California Study Research Technology 100

Xconomy

MARCH 11, 2020

At Xconomy, we are here to serve the global biotech community and help biotech and pharma companies connect, do business, and find investment opportunities.

San Diego 63

San Diego Invest Help Company 63

Xconomy

AUGUST 7, 2020

Big Pharma companies are focusing on vaccine development and a slew of biotechs are testing compounds, previously intended for a wide range of indications, as potential COVID-19 treatments. The novel coronavirus has driven the pharmaceutical industry to upend its research priorities. billion merger in the digital health sector.

Research 80

Research Develop Development Edmunds 80

socalTECH

MAY 27, 2010

Aliso Viejo-based Valeant Pharmaceuticals said today that it has completed its acquisition of Aton Pharma, a specialty pharmaceuticals firm focused on ophthalmology and other drugs. Aton Pharma was based in lawrenceville, New Jersey. The deal was worth $318M.

Acquisition 140

Acquisition 140

Xconomy

MARCH 26, 2020

Forge Therapeutics has set an agreement with Roche that gives the Swiss pharma giant the option to license a new antibiotic Forge is developing to treat serious drug-resistant bacterial lung infections.

San Diego 82

San Diego Develop Development Venture Capital 82

Xconomy

JULY 31, 2020

The biotech IPO market is buzzing but Cerevel Therapeutics is showing that there’s more than one path to the public markets. Bain Capital and Pfizer (NYSE: PFE ) launched it in 2018 with neuroscience compounds from the pharma giant’s labs. Cerevel is young, but it’s pretty far along. Now Arya and a.

Pricing 72

Pricing Acquisition Capital Marketing 72

Xconomy

JANUARY 29, 2020

Agenda topics include Successful Research & Development Models, What It Takes for Commercialization, and Building a Biotech Ecosystem in San Diego. Speakers include Jay Lichter, CEO of COI Pharma and Managing Director at Avalon Ventures; Ciara Kennedy, CEO of Amplyx; and Kim Kamdar, Partner at Domain Associates. $99

San Diego 79

San Diego Avalon Research Ideas 79

Xconomy

SEPTEMBER 17, 2019

On Monday, the clinical-stage San Diego biotech company announced it had added an experimental drug developed by Swiss pharma giant Novartis (NYSE: NVS ) to its pipeline through a licensing deal.

San Diego 90

San Diego Design Develop Development 90

socalTECH

MARCH 4, 2016

According to UCLA, it sold its royalty interest connected with prostate cancer medication Xtandi to Royalty Pharma , which includes cash payments of $1.14 UCLA said it was advised by Goldman Sachs and Gibson Dunn in the deal; Goodwin Procter advised Royalty Pharma. billion, the school said Friday afternoon.

UCLA 100

UCLA Research Los Angeles Sales 100

socalTECH

JANUARY 4, 2016

Gil Elbaz , the founder of Los Angeles-based data startup Factual , is one of the backers of a developer of lab management software for the research, biotech, and pharma industry today.

Research 100

Research Los Angeles Capital Funding 100

Xconomy

OCTOBER 10, 2018

based biotech Vernalis has closed. Ligand doesn’t have the business model of a traditional biotech. It licenses its drug development platforms and makes royalty deals with big pharma companies, Read more » Reprints | Share: UNDERWRITERS AND PARTNERS. Ligand Pharmaceuticals said Wednesday that its acquisition of U.K.-based

San Diego 63

San Diego .Net Acquisition Platform 63

Xconomy

AUGUST 7, 2019

The San Diego-based biotech has been working since 2007 to use a method known as bio-printing to come up with such a product, which Organovo (NASDAQ: ONVO ) was developing for patients with end-stage liver disease and a group of rare diseases that also necessitate organ transplantation.

San Diego 90

San Diego Outsource Development Organization Research 90

Xconomy

MAY 15, 2018

In December, Denali Therapeutics raised about $250 million in 2017’s biggest biotech IPO. The list of his portfolio company wins (if you think of raising money, going public, or being acquired as a win, which he doesn’t necessarily, read on) is impressive. This January, Juno Therapeutics was acquired by Celgene at a valuation of some $10.97

Company 70

Company Companies San Diego Venture Capital 70

socalTECH

MAY 8, 2013

Savello of Pappas Ventures, John McKearn of RiverVest, and Robert Alexander of ZS Pharma to its board as part of the funding. lumena pharmaceuticals venture capital oral therapeutics lifescience biotech liver disease' Lumena said it has added David R. READ MORE>>.

San Diego 147

San Diego Venture Capital Funding Capital 147

Xconomy

JULY 17, 2020

Venture capitalists like nothing more than pattern matching, and Domain Associates has identified one it especially prefers: licensing drug candidates from a Japanese biopharma and setting up a US company to move it through testing until Big Pharma starts nosing around.

San Diego 52

San Diego Venture Capital Startup Invest 52

socalTECH

MAY 5, 2015

Parkinson also is on the boards of Threshold Pharmaceuticals and Cerulean Pharma Inc. and had previously been on the boards of Facet Biotech and Ambit Biosciences Corporation, before both of those companies were acquired. Tocagen is initially focusing on treating an aggressive type of brain cancer, recurrent High Grade Glioma (HGG).

San Diego 100

San Diego Develop Development Company 100

socalTECH

DECEMBER 21, 2009

San Diego-based Ambit Biosciences inked a deal Friday with Astellas Pharma Inc., Tags: ambit biosciences astellas pharma biotech lifescience. where Astellas will pay the firm $40M in cash, and up to $350M in pre-commercialization milestones, in a joint partnership to develop and commercialize Ambit's FLT3 kinase inhibitors.

San Diego 140

San Diego .Net Sales Product 140

Xconomy

AUGUST 8, 2018

A new biotech has debuted today aiming to make a variety of treatments for deadly liver diseases. Some early, wide-ranging partnerships between new biotechs and Big Pharma have fallen apart in the past and have been too limiting for the biotech, but Ambys’s CEO says this deal will still allow the company to maintain control of its future.

Startup 49

Startup San Diego Study Company 49

Xconomy

OCTOBER 19, 2018

The first involved television: The federal government hopes that blaring prices in TV ads will essentially pressure drug makers into lowering them, and the pharma lobby fired back. Elsewhere, Novartis made another splashy buyout, an unusual biotech startup’s saga came to an unexpected conclusion, and the top- selling drug in.

Pricing 74

Pricing Class San Diego Venture Capital 74

socalTECH

MAY 29, 2013

Thousand Oaks-based biotech Amgen announced today that it has linked with Astellas Pharma , in a deal to reach the Japanese market with new medicines. According to the two, they are in a strategic alliance where they will provide new medicines to address the unmet medical needs of Japanese patients.

Thousand Oaks 138

Thousand Oaks Marketing Develop Development 138

Xconomy

APRIL 6, 2018

We’ll start this week with biotech deals, one featuring a couple of CAR-T heavyweights who have re-emerged after selling Kite Pharma for $12 billion. Happy Friday, everyone.

Study 55

Study Pricing Conference Marketing 55

socalTECH

JUNE 9, 2010

Tags: otonomy venture capital biopharmaceuticals biopharma middle disorder biotech lifescience pharma.

Avalon 159

Avalon San Diego Venture Capital Capital 159